2023
Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease
Tan X, Liang Y, Rajpura J, Yedigarova L, Noone J, Xie L, Inzucchi S, de Havenon A. Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease. Cardiovascular Diabetology 2023, 22: 319. PMID: 37985992, PMCID: PMC10662529, DOI: 10.1186/s12933-023-02051-8.Peer-Reviewed Original ResearchConceptsHealth care resource utilizationAtherosclerotic cardiovascular diseaseGLP-1 RAsCause health care resource utilizationPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsDPP-4i usersPeptidase-4 inhibitorsMyocardial infarctionMedical costsDPP-4iIschemic strokeReceptor agonistCardiovascular diseaseGlucagon-like peptide-1 receptor agonistsWeekly glucagon-like peptide-1 receptor agonistWeekly GLP-1 RAsCause ER visitsCause hospitalization costsCause medical costsNew adult usersClinical cardiovascular outcomesObservational cohort studyType 2 diabetesCause outpatient visits
2020
131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome
INZUCCHI S, ZINMAN B, WANNER C, FITCHETT D, ANKER S, POCOCK S, KASPERS S, GEORGE J, JOHANSEN O, JAMAL W, HANTEL S, LUND S. 131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome. Diabetes 2020, 69 DOI: 10.2337/db20-131-lb.Peer-Reviewed Original ResearchAtherosclerotic cardiovascular diseaseEMPA-REG OUTCOMEEffect of empagliflozinTotal burdenEli LillyHeart failure riskType 2 diabetesNervous system disordersTotal eventsAdvisory PanelSt. Jude MedicalLowest NNTMundipharma InternationalSanofi GenzymeCause hospitalizationCause mortalityCardiovascular mortalityFrequent hospitalizationsDohme Corp.Novo Nordisk A/SCardiovascular diseaseCardiac dimensionsHospitalization categoriesSystem disordersEmpagliflozin28-OR: How Early after Treatment Initiation Are the CV Benefits of Empagliflozin Apparent? A Post Hoc Analysis of EMPA-REG OUTCOME
VERMA S, LEITER L, SHARMA A, ZINMAN B, MATTHEUS M, FITCHETT D, GEORGE J, OFSTAD A, WANNER C, INZUCCHI S. 28-OR: How Early after Treatment Initiation Are the CV Benefits of Empagliflozin Apparent? A Post Hoc Analysis of EMPA-REG OUTCOME. Diabetes 2020, 69 DOI: 10.2337/db20-28-or.Peer-Reviewed Original ResearchCV deathEMPA-REG OUTCOMEAtherosclerotic cardiovascular diseaseHazard ratioNovo Nordisk A/SJanssen PharmaceuticalsBristol-Myers SquibbTreatment initiationEli LillyEMPA-REG OUTCOME trialCox proportional hazards modelAdvisory PanelBenefits of empagliflozinRisk of HHFRisk of hospitalizationNumber of patientsType 2 diabetesProportional hazards modelCumulative incidence curvesNovartis Pharmaceuticals CorporationPost Hoc AnalysisBayer AGBoehringer Ingelheim PharmaceuticalsEmpagliflozin 10Empagliflozin doses
2019
P6270Empagliflozin reduces the total burden of first and recurrent hospitalisations in patients with type 2 diabetes and established cardiovascular disease
McGuire D, Zinman B, Inzucchi S, Anker S, Wanner C, Kaspers S, Von Eynatten M, Johansen O, Elsasser U, Pocock S, Fitchett D, Jamal W, Hantel S, Lund S. P6270Empagliflozin reduces the total burden of first and recurrent hospitalisations in patients with type 2 diabetes and established cardiovascular disease. European Heart Journal 2019, 40: ehz746.0869. DOI: 10.1093/eurheartj/ehz746.0869.Peer-Reviewed Original ResearchEMPA-REG OUTCOME trialEffect of empagliflozinCause hospitalisationType 2 diabetesHospitalisation eventsOutcome trialsHeart failureCardiovascular diseaseMajor adverse CV eventsTotal burdenAdjusted hazard ratioAdverse CV eventsAtherosclerotic cardiovascular diseaseCox regression modelStandard of careEvent rate ratioCV deathCV eventsEmpagliflozin groupPlacebo patientsRecurrent hospitalisationsCV diseasePlacebo groupFirst eventHazard ratio